Abstract
The humoral immune response to p53 was determined in 54 individuals with colon or breast cancer and 50 healthy subjects, in an attempt to better understand the origin and significance of anti-p53 serum antibodies. The presence of anti-p53 antibodies in serum was determined by enzyme-linked immunosorbent assay using purified recombinant human p53, and results were validated by immunoprecipitation of radiolabelled p53. Immunohistochemical analysis of 28 tumours was performed to detect the accumulation of p53 protein. Antibodies against p53 were significantly more common in patients with colorectal (10 of 42) and breast (2 of 12) cancer than in healthy individuals (2 of 50). They were of both the IgM (7 of 11) and IgG (4 of 11) isotypes. There was no significant difference in prevalence of serum antibodies against p53 with respect to the p53 immunohistochemical status of the tumour or to other pathological features, including the presence of lymph node and distant metastases. These findings provide indirect evidence that, rather than arising as a result of a specific immune response, anti-p53 antibodies in individuals with cancer may represent elevated levels of naturally occurring polyreactive antibodies.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Abbreviations
- BSA :
-
bovine serum albumin
- PBS :
-
phosphate-buffered saline
- TBS :
-
TRIS-buffered saline
References
Acib-Conquy M, Avrameas S, Ternynck T (1993) Monoclonal IgG and IgM autoantibodies obtained after polyclonal activation, show reactivities similar to those of polyclonal natural autoantibodies. Mol Immunol 30:119–127
Angelopoulou K, Diamandis E, Sutherland D, Kellen J, Bunting P (1994) Prevalence of serum antibodies against the p53 tumor suppressor gene protein in various cancers. Int J Cancer 58:480–487
Avrameas S and Ternynck T (1993) The natural autoantibodies system: between hypotheses and facts. Mol Immunol 30:1133–42
Ben-Mahrez K, Sorokine I, Thierry D, Kawasumi T, Ishii S, Salmon R, Kohiyama M (1990) Circulating antibodies against c-myc oncogene in sera of colorectal cancer patients. Int J Cancer 46:35–38
Brown RE, Jarvis KL, Hyland KJ (1989) Protein measurement using bicinchoninic acid: elimination of interfering substances. Anal Biochem 180:136–139
Caron De Fromentel C, May-Leven F, Mouriesse H, Lemerle J, Chandrasekaran K, May P (1987) Presence of circulating antibodies against cellular protein p53 in a notable proportion of children with B-cell lymphoma. Int J Cancer 39:185–189
Casali P and Notkins AL (1989) CD5+B lymphocytes, polyreactive antibodies and the human B cell repertoire. Immunol Today 10:365–8
Costa A, Maraska R, Valentinis B, Savarino M, Farada A, Silvestrini R, Torelli G (1995) p53 gene point mutations in relation to p53 nucleoprotein accumulation in colorectal cancers. J Pathol 176:45–53
Cotran RS, Kumar V, Robbins SL, (eds). (1994) Pathological basis of disease, 5th edn. Saunders, Philadelphia
Crawford L, Pim D, Bulbrook R (1982) Detection of antibodies against the cellular protein p53 in the serum from patients with breast cancer. Int J Cancer 30:403–408
Davidoff AM, Dirk Inglehart J, Marks JR (1992) Immune response to p53 is dependent upon p53/HSP70 complexes in breast cancers. Proc Natl Acad Sci USA 89:3439–3442
Disis M, Calenoff E, McLaughlin G, Murphy A, Chen W, Groner B, Jeschke M, Lydon N, McGlynn E, Livingston R, Moe R, Cheever M (1994) Existent T-cell and antibody immunity to Her-2/neu protein in patients with breast cancer. Cancer Res 54:16–20
Dong X, Hamilton K, Satoh M, Wang J, Reeves W (1994) Initiation of autoimmunity to the p53 tumour suppressor protein by complexes of p53 and SV40 large T antigen. J Exp Med 17:1243–1252
Dougan G, Sherratt D (1977) The transposon Tn1 as a probe for studying ColE1 structure and function. Mol Gen Genet 151:151–160
Houbiers JGA, Van de Berg SH, Watering LMG van de, Tollenaar RAEM, Brand A, Velde CJH van de, Melief CJM (1995) Antibodies against p53 are associated with poor prognosis of colorectal cancer. Br J Cancer 72:637–641
Kotera Y, Fontenot J, Pecher G, Metzgar R, Finn O (1994) Humoral immunity against a tandem repeat epitope of human mucin MUC-1 in sera from breast, pancreatic, and colon cancer patients. Cancer Res 54:2856–2860
Laemmli K (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227:680–685
Levine L, Momand J, Finlay C (1991) The tumour suppressor gene. Nature 351:453–456
Lubin R, Schlichtholz B, Bengoufa D, et al. (1993) Analysis of p53 antibodies in patients with various cancers define B-cell epitopes of human p53: distribution on primary structure and exposure on protein surface. Cancer Res 53:5872–5876
Mudenda B, Green J, Green B, Jenkins J, Robertson L, Tarunina M, Leinster S (1994) The relationship between serum p53 antibodies and characteristics of human breast cancer. Br J Cancer 69:1115–1119
Nigro JM, Baker SJ, Preisinger AC, Jessup JM, Hostetter R, Cleary K, Bigner SH, Davidson N, Baylin S, Devilee P, et al. (1989) Mutations in the p53 gene occur in diverse human tumour types. Nature 342:705–708
Old LJ (1981) Cancer Immunology: the search for specificity. Cancer Res 41:361–375
Pupa SM, Menard S, Andreola S, Colnaghi MI (1993) Antibody response against the c-erbB-2 oncoprotein in breast carcinoma patients. Cancer Res 53:5864–5866
Purdie CA, O'Grady J, Piris J, Wyllie AH, Bird CC (1991) p53 expression in colorectal tumors. Am J Pathol 138:807–813
Sancar A, Wharton RP, Seltzer S, Kacinsky BM, Clark ND, Rupp WD (1981) Identification of theuvrA gene product. J Mol Biol 184:45–62
Schlichtholz B, Legros Y, Gillet D, Gailard C, Marty M, Lane D, Calvo F, Soussi T (1992) The immune response to p53 in breast cancer patients is directed against immunodominant epitopes unrelated to the mutational hotspot. Cancer Res 52:6380–6384
Sorokine I, Ben-Mahrez K, Sorokine I, Braconne A, Thierry D, Imamoto F, Ishii S, Kohiyama M (1991) Presence of circulating anti-c-myb oncogene product antibodies in human serum. Int J Cancer 47:665–669
Towbin H, Staehelin T, Gordon J (1979) Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets. Proc Natl Acad Sci USA 76:4350–4354
Winter SF, Minna JD, Johnson BE, Takahashi T, Gazdar AF, Carbone DP (1992) Development of antibodies against p53 in lung cancer patients appears to be dependent on the type of p53 mutation. Cancer Res 52:4168–4174
Author information
Authors and Affiliations
Additional information
The work was carried out with the aid of grant support from St Vincent's Clinic Foundation
Rights and permissions
About this article
Cite this article
Coomber, D., Hawkins, N.J., Clark, M. et al. Characterisation and clinicopathological correlates of serum anti-p53 antibodies in breast and colon cancer. J Cancer Res Clin Oncol 122, 757–762 (1996). https://doi.org/10.1007/BF01209124
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01209124